Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antithrombotic agents.

J Hirsh1, J I Weitz

  • 1Hamilton Civic Hospitals Research Centre and Department of Medicine, Ontario, Canada.

Lancet (London, England)
|May 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.

Annals of internal medicine·1997
Same author

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

Circulation·1997
Same author

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.

Circulation·1996
Same author

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.

Haemostasis·1996
Same author

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.

Blood·1996
Same author

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.

Archives of internal medicine·1996
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

New antithrombotic agents address limitations of older drugs like heparin and coumarins. Novel anticoagulants and antiplatelet drugs offer improved efficacy and safety for preventing thrombosis.

Area of Science:

  • Pharmacology
  • Biotechnology
  • Cardiovascular Medicine

Background:

  • Clinical needs drive the development of advanced antithrombotic therapies.
  • Biotechnology enables the creation of drugs targeting specific thrombogenesis pathways.
  • Existing anticoagulants like heparin and coumarins have limitations requiring safer, more effective alternatives.

Purpose of the Study:

  • To review the advancements in antithrombotic agents.
  • To discuss novel anticoagulants and antiplatelet drugs.
  • To compare the efficacy and safety profiles of new agents versus traditional therapies.

Main Methods:

  • Review of clinical evaluations of new antithrombotic drugs.
  • Analysis of pharmacological mechanisms of action for novel agents.

Related Experiment Videos

  • Comparison of clinical outcomes and safety data for various antithrombotic classes.

    • Main Results:

    • Low-molecular-weight heparin and direct thrombin inhibitors overcome heparin's limitations.
    • Orally active direct inhibitors of thrombin and factor Xa show promise in replacing coumarins.
    • Inhibitors of adenosine diphosphate receptor and glycoprotein IIb/IIIa antagonists are more effective than aspirin.

    Conclusions:

    • New biotechnologically derived antithrombotic agents offer improved pharmacokinetic and safety profiles.
    • Novel anticoagulants and antiplatelet drugs represent significant progress in managing thrombotic disorders.
    • The clinical application of these advanced agents is expanding, improving patient outcomes.